NCT00742560 2018-01-10A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaAbbViePhase 2 Completed101 enrolled 20 charts